Seeing green, AstraZeneca lays down £100M for 15-year renewable gas project in UK
14 Sep 2023
Preview
Source: FiercePharma
The biomethane facility will use locally grown crops as fuel to help power AstraZeneca sites in the U.K.
AstraZeneca, often at the forefront of biopharma's sustainability efforts, is making a big play to support renewable natural gas in its home country.
Through a 100 million pound sterling ($124 million), 15-year commitment with U.K. clean energy provider Future Biogas, the partners plan to establish the first "unsubsidised industrial-scale supply of biomethane gas" in the U.K., AstraZeneca said in a release.
Once operational, the biomethane facility will use locally grown crops as feedstock, supporting farms and initiating the development of a “circular agricultural economy,” AZ said.
AZ’s Macclesfield facility is the U.K.’s largest drug development and manufacturing site. The site will undergo a “major refit” of its heat and power plant to slash emissions.
The partners hope the move will provide a blueprint for other organizations looking to scale up renewable natural gas and cut emissions.
As for AstraZeneca, the company aims to halve its carbon footprint by 2030 and become net-zero by 2045 "at the latest." And the partnership with Future Biogas is only one of AZ's recent sustainability efforts.
Earlier this summer, the company expanded its AZ Forest program with a $400 million investment that it will use to establish new or expanded forestry programs in Brazil, India, Vietnam, Ghana and Rwanda.
Then in June, AZ linked up with U.S. renewable natural gas (RNG) producer Vanguard Renewables to use RNG at its Newark, Delaware, campus. That deal will bring the equivalent of energy resources needed to heat more than 17,800 U.S. homes for a year.
And last month, the eco-minded company partnered with European renewable energy provider Stratkraft on wind power deliveries to increase Sweden’s supply of renewable electricity. In that deal, AZ agreed to buy 200 gigawatt-hours per year for 10 years, which corresponds to roughly 80% of the company’s total electricity needs at its Gothenburg research facility and its Södertälje manufacturing plant.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.